No Data
No Data
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ATLANTA, June 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or the "Company"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners
Express News | HC Wainwright & Co. Reiterates Buy on Alimera Sciences, Maintains $6 Price Target
Alimera Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 76.99% HC Wainwright & Co. → $6 Reiterates Buy → Buy 03/25/2024 194.99% Maxim Group → $10 Initi
Robust Growth and Promising Trials: Buy Rating for Alimera Sciences
Alimera Sciences: A Strong Buy on Robust Q1 Growth, Strategic Acquisitions, and Positive Financial Indicators
Alimera Sciences Inc (ALIM) Q1 2024 Earnings Call Transcript Highlights: Soaring Revenues and ...
No Data